The Choice should be Yours: Diabetes-related Distress by Insulin Delivery Method for Patients with Type 1 Diabetes.
Clicks: 384
ID: 11680
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
66.4
/100
384 views
278 readers
Trending
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #2 of 7 articles by views in diabetes technology & therapeutics
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
ADA recommends psychosocial assessment for people with diabetes, including diabetes-related distress. Elevated diabetes-related distress is associated with poor self-management, lower medication adherence, and poorer quality of life. Insulin delivery methods are multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII). Since people with Type 1 diabetes mellitus (T1DM) require comprehensive insulin therapy to manage blood glucose, we explored the association of insulin delivery methods and diabetes distress in this group.The US Air Force Diabetes Center of Excellence (DCOE), a specialty clinic for adults who are military health system (MHS) beneficiaries, administers the validated 17-item Diabetes-related Distress Scale (DDS-17) as part of standard care. Patient data were analyzed from June 2015 through August 2016 using SPSS version 22. Patients were free to choose method of insulin delivery with minimal or no additional cost.There were 203 patients with T1DM who completed the DDS-17 as part of standard care during the time period. Patients were categorized as CSII (57.6%) or MDI (42.4%). Women were significantly more likely to choose MDI over CSII than men (p =0.003). DDS-17 scores were low in both groups, and there were no significant differences in DDS-17 by insulin delivery method. Furthermore, no significant differences were found in HbA1c between CSII (7.9% or 63 mmol/mol) and MDI (8.1% or 65 mmol/mol) users (p=0.22) and no significant differences in BMI between patients using CSII (M=28.33 kg/m2) and MDI (28.49 kg/m2) users (p=0.15).Our study demonstrated that if patients are relatively free to choose the insulin delivery method (minimal or no financial constraints), there were no differences in diabetes distress scores, HbA1c, or BMI between CSII and MDI. Therefore, people with T1DM may benefit from choosing the method of insulin delivery that will enable them to achieve individual goals and manage diabetes-related distress.
| Reference Key |
wardian2019thediabetes
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Wardian, Jana L;True, Mark W;Folaron, Irene;Colburn, Jeffrey A;Tate, Joshua M;Beckman, Darrick J; |
| Journal | diabetes technology & therapeutics |
| Year | 2019 |
| DOI |
10.1089/dia.2019.0228
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.